Skip to main content
. 2021 Dec 1;13(1):107–116. doi: 10.1111/1759-7714.14232

TABLE 3.

Baseline characteristics before the initiation of alectinib (n = 61)

Number (percentage)
Reasons for the discontinuation of crizotinib
Disease progression 52 (85.2%)
Severe adverse events 7 (11.5%)
Patient preferences 2 (3.3%)
Median age 49 (range 28, 81)
<65 53 (86.9%)
≥65 8 (13.1%)
ECOG
0–1 40 (65.6%)
≥2 21 (34.4%)
CNS metastases
Yes 38 (62.3%)
No 23 (37.7%)
Distant organs involved
0 3 (4.9%)
1–2 38 (62.3%)
≥3 20 (32.8%)
Target lesions
Yes 46 (75.4%)
No 15 (24.6%)